Population pharmacokinetics of moxifloxacin, cycloserine, p -aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis

Highlights • Population pharmacokinetic models of second-line anti-tuberculosis (TB) drugs in multi-drug-resistant TB were developed. • Dosages of second-line anti-TB drugs were slightly different from previous studies. • Pharmacokinetic parameters of moxifloxacin were influenced by patients' w...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of antimicrobial agents Vol. 49; no. 6; pp. 677 - 687
Main Authors Chang, Min Jung, Jin, Byunghak, Chae, Jung-woo, Yun, Hwi-yeol, Kim, Eun Sun, Lee, Yeon Joo, Cho, Young-Jae, Yoon, Ho Il, Lee, Choon-Taek, Park, Kyoung Un, Song, Junghan, Lee, Jae-Ho, Park, Jong Sun
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.06.2017
Subjects
Adult
Aged
Aged, 80 and over
Antitubercular Agents - administration & dosage
Antitubercular Agents - pharmacokinetics
Chromatography
Female
Humans
Infectious Disease
Injections, Intramuscular
Male
Middle Aged
Models, Statistical
Multi-drug-resistant tuberculosis
Plasma - chemistry
Population pharmacokinetics
Prospective Studies
Second-line anti-tuberculosis drugs
Tandem Mass Spectrometry
Tuberculosis, Multidrug-Resistant - drug therapy
United States
Population pharmacokinetics
Second-line anti-tuberculosis drugs
p-Aminosalicylic acid
Kanamycin
Moxifloxacin
Multi-drug-resistant tuberculosis
Cycloserine
Online AccessGet full text

Cover

More Information
Summary:Highlights • Population pharmacokinetic models of second-line anti-tuberculosis (TB) drugs in multi-drug-resistant TB were developed. • Dosages of second-line anti-TB drugs were slightly different from previous studies. • Pharmacokinetic parameters of moxifloxacin were influenced by patients' weight.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0924-8579
1872-7913
DOI:10.1016/j.ijantimicag.2017.01.024